http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 27 Feb 2026 16:02:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26081419.html si-local-file:///var/storage/secattach/20260227/26081419.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26081419.html Fri, 27 Feb 2026 16:02:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26081419.html si-local-file:///var/storage/secattach/20260227/26081419.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Coastlands+Capital+LP/26081419.html Fri, 27 Feb 2026 16:02:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Feb+20/26037019.html si-local-file:///var/storage/secattach/20260220/26037019.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Feb+20/26037019.html Fri, 20 Feb 2026 17:01:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Feb+20/26037019.html si-local-file:///var/storage/secattach/20260220/26037019.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Feb+20/26037019.html Fri, 20 Feb 2026 17:01:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26011327.html si-local-file:///var/storage/secattach/20260217/26011327.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26011327.html Tue, 17 Feb 2026 14:49:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26011327.html si-local-file:///var/storage/secattach/20260217/26011327.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26011327.html Tue, 17 Feb 2026 14:49:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26009693.html si-local-file:///var/storage/secattach/20260217/26009693.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26009693.html Tue, 17 Feb 2026 11:36:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26009693.html si-local-file:///var/storage/secattach/20260217/26009693.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26009693.html Tue, 17 Feb 2026 11:36:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+AMERIPRISE+FINANCIAL+INC/26008700.html si-local-file:///var/storage/secattach/20260217/26008700.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+AMERIPRISE+FINANCIAL+INC/26008700.html Tue, 17 Feb 2026 10:10:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+AMERIPRISE+FINANCIAL+INC/26008700.html si-local-file:///var/storage/secattach/20260217/26008700.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+AMERIPRISE+FINANCIAL+INC/26008700.html Tue, 17 Feb 2026 10:10:00 -0500 KTTA O.47854289 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+to+Present+at+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26005698.html <p style="padding-left:0pt;"><em>– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –</em><br /><em>– Webcast may be accessed </em><a href="https://www.globenewswire.com/Tracker?data=IxbyJLIxkpBkOJiU1VX5GWhVv-ZeYNhaQRdgTF5_Fmq1A-RudQ8O5-yW7N-nZXrhGvOxDKJqXTyrQlH2MJ3TPsKo1emyDohY2dGi1-ELEz5RxcBBBkfSzfuMRWWtSPIM1MbkjhAOyhNn5zosl6PtXw40DYmnlzMETEW-8zohN-VogE4ZDIPhAlXuLg5Wng2y" rel="nofollow" target="_blank"><em><u>here</u></em></a><em> –</em></p> <p align="justify" style="padding-left:0pt;">MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ZdnvRqCip5x5uO4Jj45BCb3ivDcANO-x4WEc_rv5rRz3KHcNxTpFZfIrh05jD1UQuQJq4HLOjvhO1f-Bi0yORyGAuH229vV9uBrgEwS2ZGU=" rel="nofollow" target="_blank"><u>Pasithea Therapeutics Corp.</u></a> (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.</p> <p http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+to+Present+at+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26005698.html Tue, 17 Feb 2026 07:01:00 -0500 KTTA http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+to+Present+at+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26005698.html <p style="padding-left:0pt;"><em>– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –</em><br /><em>– Webcast may be accessed </em><a href="https://www.globenewswire.com/Tracker?data=IxbyJLIxkpBkOJiU1VX5GWhVv-ZeYNhaQRdgTF5_Fmq1A-RudQ8O5-yW7N-nZXrhGvOxDKJqXTyrQlH2MJ3TPsKo1emyDohY2dGi1-ELEz5RxcBBBkfSzfuMRWWtSPIM1MbkjhAOyhNn5zosl6PtXw40DYmnlzMETEW-8zohN-VogE4ZDIPhAlXuLg5Wng2y" rel="nofollow" target="_blank"><em><u>here</u></em></a><em> –</em></p> <p align="justify" style="padding-left:0pt;">MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ZdnvRqCip5x5uO4Jj45BCb3ivDcANO-x4WEc_rv5rRz3KHcNxTpFZfIrh05jD1UQuQJq4HLOjvhO1f-Bi0yORyGAuH229vV9uBrgEwS2ZGU=" rel="nofollow" target="_blank"><u>Pasithea Therapeutics Corp.</u></a> (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.</p> <p http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+to+Present+at+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26005698.html Tue, 17 Feb 2026 07:01:00 -0500 KTTA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./25988440.html si-local-file:///var/storage/secattach/20260212/25988440.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./25988440.html Thu, 12 Feb 2026 09:02:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./25988440.html si-local-file:///var/storage/secattach/20260212/25988440.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Pasithea+Therapeutics++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./25988440.html Thu, 12 Feb 2026 09:02:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Pasithea+Therapeutics++++++++++++++++/25923759.html si-local-file:///var/storage/secattach/20260130/25923759.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Pasithea+Therapeutics++++++++++++++++/25923759.html Fri, 30 Jan 2026 16:16:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Pasithea+Therapeutics++++++++++++++++/25923759.html si-local-file:///var/storage/secattach/20260130/25923759.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Pasithea+Therapeutics++++++++++++++++/25923759.html Fri, 30 Jan 2026 16:16:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Jan+28/25908871.html si-local-file:///var/storage/secattach/20260128/25908871.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Jan+28/25908871.html Wed, 28 Jan 2026 16:16:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Jan+28/25908871.html si-local-file:///var/storage/secattach/20260128/25908871.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pasithea+Therapeutics+++++For%3A+Jan+28/25908871.html Wed, 28 Jan 2026 16:16:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Pasithea+Therapeutics++++++++++++++++/25903451.html si-local-file:///var/storage/secattach/20260128/25903451.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Pasithea+Therapeutics++++++++++++++++/25903451.html Wed, 28 Jan 2026 06:07:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Pasithea+Therapeutics++++++++++++++++/25903451.html si-local-file:///var/storage/secattach/20260128/25903451.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Pasithea+Therapeutics++++++++++++++++/25903451.html Wed, 28 Jan 2026 06:07:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Pasithea+Therapeutics++++++++++++++++/25890520.html si-local-file:///var/storage/secattach/20260126/25890520.html http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Pasithea+Therapeutics++++++++++++++++/25890520.html Mon, 26 Jan 2026 08:00:00 -0500 KTTA O.47854289 http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Pasithea+Therapeutics++++++++++++++++/25890520.html si-local-file:///var/storage/secattach/20260126/25890520.html http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Pasithea+Therapeutics++++++++++++++++/25890520.html Mon, 26 Jan 2026 08:00:00 -0500 KTTA O.47854289 http://www.streetinsider.com/Guidance/Pasithea+Therapeutics+provides+updated+clinical+trial+timelines/25840501.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced updated timelines for its ongoing clinical trials of PAS-004, an oral macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 associated plexiform neurofibromas and advanced cancer patients.</p><p>The company has completed enrollment of 12 patients through the first four dose cohorts in Part A of its Phase 1/1b clinical trial in adult patients with NF1-PN. Pasithea plans to present data from this study in the second half of 2026, including efficacy data through the six-month timepoint for both plexiform and cutaneous neurofibromas, along with safety, tolerability and pharmacokinetic data.</p><p>For its Phase 1 clinical trial in http://www.streetinsider.com/Guidance/Pasithea+Therapeutics+provides+updated+clinical+trial+timelines/25840501.html Tue, 13 Jan 2026 07:03:48 -0500 KTTA KTTAW http://www.streetinsider.com/Guidance/Pasithea+Therapeutics+provides+updated+clinical+trial+timelines/25840501.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced updated timelines for its ongoing clinical trials of PAS-004, an oral macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 associated plexiform neurofibromas and advanced cancer patients.</p><p>The company has completed enrollment of 12 patients through the first four dose cohorts in Part A of its Phase 1/1b clinical trial in adult patients with NF1-PN. Pasithea plans to present data from this study in the second half of 2026, including efficacy data through the six-month timepoint for both plexiform and cutaneous neurofibromas, along with safety, tolerability and pharmacokinetic data.</p><p>For its Phase 1 clinical trial in http://www.streetinsider.com/Guidance/Pasithea+Therapeutics+provides+updated+clinical+trial+timelines/25840501.html Tue, 13 Jan 2026 07:03:48 -0500 KTTA KTTAW http://www.streetinsider.com/Corporate+News/Pasithea+Therapeutics+provides+updated+clinical+trial+timelines/25840501.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced updated timelines for its ongoing clinical trials of PAS-004, an oral macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 associated plexiform neurofibromas and advanced cancer patients.</p><p>The company has completed enrollment of 12 patients through the first four dose cohorts in Part A of its Phase 1/1b clinical trial in adult patients with NF1-PN. Pasithea plans to present data from this study in the second half of 2026, including efficacy data through the six-month timepoint for both plexiform and cutaneous neurofibromas, along with safety, tolerability and pharmacokinetic data.</p><p>For its Phase 1 clinical trial in http://www.streetinsider.com/Corporate+News/Pasithea+Therapeutics+provides+updated+clinical+trial+timelines/25840501.html Tue, 13 Jan 2026 07:03:48 -0500 KTTA KTTAW